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Introduction:  Haemagglutination-inhibition  (HI)  antibody  titer is a  correlate  of  protection  against
inﬂuenza;  its persistence  after infection  or vaccination  is  important  to  determining  susceptibility  to
subsequent  infection.  Few  studies,  however,  have  reported  longitudinal  data regarding  the magnitude
and  duration  of  HI  protection  following  natural  seasonal  inﬂuenza  A infection.
Methods: Using  French  inﬂuenza  cohort  study  data  collected  from  2008  to 2010,  we investigated
persistence  of  serological  protection  among  subjects  according  to inﬂuenza-like  illness  (ILI) and
laboratory-conﬁrmed  seasonal  2007  inﬂuenza  A(H1N1)  infection  status  at inclusion  in  2008  (ILI-A(H1N1)
positive,  ILI-A(H1N1)  negative,  or no-ILI).  Antibody  titers  against  seasonal  2007  A(H1N1)  were  deter-
mined  using  the  HI technique  for sera.  Regression  models  for interval-censored  data  were  used  to  estimate
geometric  mean  titers  (GMT)  for HI assays.  A logistic  regression  model  adjusted  for age  group  (subjects
<30,  30–50  and  >50 years  old)  was  used  to  quantify  the association  between  HI titer  and  protection
against  infection.
Results: Based  on  310 total  subjects,  inﬂuenza  A(H1N1)  infection  was  conﬁrmed  in 39 of 115 ILI  subjects  at
inclusion.  GMT  associated  with  50%  probability  of protection  among  ILI subjects  decreased  with  age  group
(subjects  <30  yo:  GMT of  40.8  was  associated  with  50%  [95CI:  29.3%;  70.7%]  probability  of protection,
subjects  30–50  yo:  26.8  [95CI:  34.4%;  65.6%]  and subjects  >50  yo:  8.9 [95CI:  15.3%;  84.7%]).  GMT  declined
after  the  ﬁrst  annual  study  visit  among  ILI-A(H1N1)  positive  subjects  but  remained  higher  compared
to  inclusion  at the  2010  study  visit  (41.5  [95CI:  34.8;  49.5], p =  0.0157).  GMT  remained  stable  among
ILI-A(H1N1)  negative  subjects  (p =  0.7502),  but  decreased  among  no-ILI  subjects  (p < 0.0001).
Conclusion:  Our  results  conﬁrm  the  positive  relationship  between  HI titer  and  probability  of protec-
tion  among  naturally  infected  subjects,  and  provides  evidence  that  protection  associated  with  HI titer
varies  with  age.  This  longitudinal  analysis  suggests  the rise  in HI titers  following  seasonal  2007  inﬂuenza
A(H1N1)  infection  may  persist  into  subsequent  inﬂuenza  seasons.
ublis© 2015  The  Authors.  P
. IntroductionInﬂuenza represents an important public health burden; a life-
ime of exposure to numerous inﬂuenza viruses results in an
∗ Corresponding author. Tel.: +33 144738451.
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ttp://dx.doi.org/10.1016/j.vaccine.2015.09.016
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article unhed  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
estimated 10 infections if never vaccinated [1]. Cohort studies
have provided valuable information concerning the epidemiology
of inﬂuenza [2–7], however, speciﬁc knowledge regarding the per-
sistence of the immune response is limited [8].Exposure to the inﬂuenza virus activates an immune response
that includes the production of virus-speciﬁc antibodies. The
concentration of antibodies targeting two virus proteins, haemag-
glutinin (HA) and neuraminidase (NA), provides an indication of
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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he level of protection an individual has against infection, and are
herefore considered “correlates of protection” [9,10]. In the 1970s,
t was demonstrated that haemagglutination-inhibiting (HI) anti-
ody titers of 40 were associated with 50% clinical protection in the
vent of inﬂuenza A2 or B exposure [11]. Although widely accepted
nd used as a major endpoint in vaccine efﬁcacy studies [12,13],
ew studies have been performed to validate this threshold among
aturally infected subjects [14] or considered age-related differ-
nces in protection. Further to this, little is known regarding how
rotection changes over time.
In this study we aimed to conﬁrm the association between HI
iter and protection against natural inﬂuenza infection, investigate
ge-related differences in protection, and to study the persistence
f the antibody response. Evaluation of HI titer durability following
nfection is of interest to discerning susceptibility of individuals
o recurrent infections, and may  have important implications on
opulation immunity.
. Methods
.1. Patient recruitment/participation
Data from the FLUREC study, a French cohort designed to study
ecurrent inﬂuenza infection, was used in this study. Thirty-six
rench metropolitan general practitioners (GP) participating in the
entinelles network recruited subjects during GP visits. Subject
ecruitment was  stratiﬁed by reason for medical visit (inﬂuenza-
ike illness (ILI) or no-ILI related illness) and age (10-year age
roups). An ILI was deﬁned as a sudden onset of fever (38 ◦C)
ccompanied by muscle soreness and cough. Subjects performed
n inclusion visit and a total of 3 annual study visits throughout the
ollow-up period. More details regarding study design and subject
ecruitment can be found elsewhere [15].
.2. Data collection
Study data was collected and entered on electronic case report
orms by GPs. Data regarding medical history (including chronic
onditions, inﬂuenza episodes and/or inﬂuenza vaccination in the
ast two years) and sociodemographic information were collected
t inclusion for all subjects. Symptoms data and duration were
ollected for subjects reporting an ILI-related illness at inclusion.
uring annual study visits, information regarding clinical history
ILI-related illnesses, vaccination status) was documented. Nasal
wabs (VIROCULT®, KITVIA, Labarthe Inard, France) were collected
t inclusion for ILI subjects. Serological blood samples were col-
ected for ILI subjects at inclusion, and for all study subjects at the
nnual visits. Nasal swabs and blood samples were collected in the
vent of an ILI episode during study follow-up at a dedicated study
isit.
.3. Surveillance data
Inﬂuenza A/Brisbane/59/2007(H1N1) (62%), A/Brisbane/
0/2007(H3N2) (2%) and inﬂuenza B/Florida/4/2006 (36%) cir-
ulated during the 2007–2008 seasonal epidemic which started
 January and ended on 9 March 2008 [16]. The 2008–2009
nﬂuenza epidemic began on 15 December 2008 and ended on
2 February 2009, and was characterized by the predominant
irculation of the inﬂuenza A/Brisbane/10/2007(H3N2) (85–88%)
ompared to inﬂuenza B (10–12%) (B/Victoria/2/87 lineage and
/Yamagata/16/88 lineage were detected in Europe) [17,18]. The
009–2010 A(H1N1) pandemic began in France on 5 October 2009
nd ended on 11 January 2010; inﬂuenza A/California/7/2009
H1N1pdm09) represented 95% of the viruses circulating during
his season [19].33 (2015) 7015–7021
The 2007–2008 seasonal inﬂuenza vaccine was composed
of the A/Solomon Islands/3/2006 (H1N1), A/Wisconsin/67/2005
(H3N2) and B/Malaysia/2506/2004 strains [20]. Seasonal vaccines
for 2008–2009 and 2009–2010 inﬂuenza seasons contained the
A/Brisbane/59/2007 (H1N1) strain.
2.4. Laboratory procedures
2.4.1. RT-PCR
Nasopharyngeal swabs collected at inclusion were tested for the
presence of the seasonal 2007 A(H1N1) virus using one step real
time RT-PCR; procedures have been previously described [15].
2.4.2. Haemagglutination inhibition (HI) titer
HI titers against seasonal A(H1N1) were determined using
the haemagglutination-inhibiting technique for serological sam-
ples collected at inclusion and annual study visits using
an A/Paris/6/2007 (H1N1)-like strain. Serial two-fold dilutions
(1/10–1/1280) of heat-inactivated sera were used in these exper-
iments. Serum HI titer was determined to be the reciprocal of the
highest serial dilution at which complete inhibition of haemagglu-
tination occurred in two  independent readings [21]. Two controls
were present on each plate; serum HI titer readings were adjusted
according to control results. Samples for which HI titer was unde-
tectable or highly elevated were double veriﬁed. Intralaboratory
variation assessments were performed to evaluate the proportion
of serum samples in which a >2-fold and >4-fold difference was
identiﬁed in replicate assays [22]; all samples were found to be
within a 2-fold range.
2.5. Statistical methods
Infection was deﬁned as laboratory-conﬁrmed seasonal 2007
A(H1N1) on a nasopharyngeal swab collected at inclusion. Three
groups were deﬁned according to presence of ILI and infection sta-
tus at inclusion: ILI-A(H1N1) positive, ILI-A(H1N1) negative, and
no-ILI. Analyses were restricted to subjects whose infection sta-
tus could be determined at inclusion and samples for which all
serological and vaccination data was complete. We  selected ILI
subjects with an inclusion blood sample collected before the end
of the 2007–2008 seasonal epidemic and, to limit the possibil-
ity of elevated titers associated with infection among ILI subjects,
within 5 days of the inclusion visit. Subjects reporting seasonal
(2008–2009, 2009–2010) or A(H1N1)pdm09 (pandemic) vaccina-
tion during study follow-up were censored at the given study visit
date. p Values <0.05 were determined to be signiﬁcant.
Differences in baseline characteristics between ILI and no-ILI
subjects were studied using the Wilcoxon rank-sum test for contin-
uous covariates and the Fisher exact test for categorical covariates.
Regression models for interval-censored data were used to esti-
mate geometric mean titers (GMT) for HI assays [23] and to
compare GMT  between groups. Evolution of GMT  over time was
evaluated using these models (accounting for repeated data). The
association between (log 2-transformed) HI estimates (GMT of the
upper and lower bounds of the interval censored HI measures) at
inclusion and protection against infection was modeled using logis-
tic regression among all ILI subjects and adjusted for age at inclusion
using three age groups (subjects <30 years, 30–50 years and >50
years old). Keeping with previously published work [24,25], we
deﬁne protection in this analysis as a negative result by PCR for
inﬂuenza infection.
Statistical analyses were performed with the R statistical pro-
gram (v2.15.2).
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nd  number of serological samples obtained at inclusion and annual study visits. * In
o-ILI  (n = 2).
.6. Ethics
This study received French ethics committee (Comité de Protec-
ion des Personnes Ile-de-France V (no. 07715)) and Data Protection
uthority approval (no. 1261460) and all study participants pro-
ided written informed consent.
. Results
Out of a total of 382 subjects included in the study in 2008,
57 provided at least one serological sample (Fig. 1). ILI subjects
ith incomplete inclusion visit data (n = 4), whose inclusion sam-
le was obtained >5 days after inclusion visit (n = 30) and after
he seasonal 2007 epidemic (n = 12) were excluded. One additional
ubject was not included due to seasonal vaccination during ﬁrst
tudy visit in 2009. Seasonal vaccination was reported (or missing)
uring the 2009 (n = 107) and 2010 study visits (n = 9). Five other
ubjects reported pandemic vaccination. This analysis is therefore
ased on 716 samples from 310 subjects. Sixty-nine percent of sub-
ects (n = 213) provided at least two blood samples, 48% (n = 148)
rovided at least three blood samples and 15% (n = 45) provided
our blood samples. Regarding the timing of the annual study visits,
9%, 86%, and 100% were conducted before the start of the seasonal
pidemic period for the 2008, 2009 and 2010 annual study visits,
espectively (Fig. 2). and seasonal 2007 A(H1N1) infection status (PCR for ILI subjects only) at inclusion,
s missing vaccine status: ILI-A(H1N1) positive (n = 2); ILI-A(H1N1) negative (n = 3);
Study subjects were 18-85 years old at inclusion; No-ILI subjects
were older than ILI-subjects (Median: 53 (IQR: 36; 66) vs Median:
44 (IQR: 35; 57), p = 0.0206) and were more likely to have had sea-
sonal 2007 vaccination (No-ILI: 76 (39%) vs 24 (21%); p = 0.0010). ILI
and no-ILI subjects also differed at baseline with regard to house-
hold size (No-ILI: Median 2 (IQR: 2; 4) vs ILI subjects: Median 1
(IQR: 1; 3); p < 0.0001), history of hypercholesteremia (No-ILI: 35
(18%) vs ILI subjects: 8 (7%); p = 0.0064), and cardiovascular illness
(No-ILI: 62 (32%) vs ILI subjects: 24 (21%); p = 0.0485) (Table 1).
Of the 115 ILI subjects included in the protection analysis, 39
were found to have laboratory conﬁrmed A(H1N1) infection. Pro-
portion of infection decreased with increasing age group, with the
highest proportion (52%) of infection among the subjects <30 years
old (p < 0.0001). ILI–A(H1N1) positive subjects had lower GMT  at
inclusion compared to ILI–A(H1N1) negative subjects (Fig. 3) (33.8
[95CI: 29.8; 38.4] vs 43.5 [95CI: 39.0; 48.6], p = 0.0056).
Over study follow-up, 3 subjects were diagnosed with sea-
sonal A(H3N2) infection (2008–2009 season) and 1 subject with
A(H1N1)pdm09 infection (2009–2010); all infected subjects were
enrolled in the no-ILI group at inclusion.3.1. HI protection curves
Serological titer against seasonal 2007 A(H1N1) at inclusion
among ILI subjects (ILI-A(H1N1) positive, n = 39; ILI-A(H1N1)
7018 R.M. Delabre et al. / Vaccine 33 (2015) 7015–7021
Fig. 2. Weekly incidence of inﬂuenza-like illnesses (ILIs) in France according to French Sentinel network and monthly study blood collection from January 2008 to November
2010.  Dotted line (left scale) ILI weekly incidence per 100,000; monthly study blood collection (right scale), gray bars represent ILI inclusion visit samples and black bars
represent annual study visit samples.
Table 1
Comparison of baseline characteristics between ILI (n = 115) and no-ILI subjects (n = 195) at inclusion.
No-ILI (n = 195) ILI (n = 115) p
Covariate
Age (yrs)—median (IQR) 53 (36; 66) 44 (35; 57) 0.0206
Number of household members—median (IQR) 2 (2; 3.5) 1 (1; 3) <0.0001
Sex  (Female)—N (%) 111 (57) 68 (59) 0.7225
Asthma—N  (%) 8 (4) 6 (5) 0.7782
ILI  season 2006–2007*—N (%) 27 (14) 13 (12) 0.7246
Smoker†—N (%) 41 (21) 29 (27) 0.2595
Chronic Illness—N (%) 100 (51) 47 (41) 0.0790
Hypercholesterolemia—N  (%) 35 (18) 8 (7) 0.0064
Cardiovascular—N  (%) 62 (32) 24 (21) 0.0485
Respiratory—N  (%) 11 (6) 10 (9) 0.3515
Other—N  (%) 19 (10) 5 (4) 0.1222
2007–2008 seasonal vaccination—N (%) 76 (39) 24 (21) 0.0010
n
t
b
o
s
G
i
a
s
a
F
s* Indicate unspeciﬁed values (ILI season 2006–2007, n = 9).
† Indicate covariate missing values (Smoker, n = 8).
egative, n = 76) was positively associated with probability of pro-
ection against A(H1N1) infection. We  found signiﬁcant differences
etween older (>50 years old) and younger subjects (<30 years
ld) (p = 0.0091); no signiﬁcant differences were found between
ubjects 30–50 years old and subjects <30 years old (p = 0.4271).
MT  associated with 50% probability of protection decreased withncreasing age: we predicted a GMT  of 40.8 at inclusion was associ-
ted with 50% [95CI: 29.3%; 70.7%] probability of protection among
ubjects <30 years old; GMT  26.8 for 50% [95CI: 34.4%; 65.6%]
mong subjects 30–50 years old; GMT  8.9 for 50% [95CI: 15.3%;
ig. 3. Cumulative distribution curves for 2007H1N1 titers at inclusion among ILI
ubjects (n = 115) according to seasonal 2007 A(H1N1) infection status by PCR.84.7%] among subjects >50 years old (Fig. 4). Overall, increasing
serological titer was associated with a steady increase in proba-
bility of protection, however, the increase in protection was  much
smaller for HI titers >80.
3.2. Evolution of antibody titerAmong ILI–A(H1N1) positive subjects highest GMT  (54.0 [95CI:
45.3; 64.4]) was observed at the ﬁrst annual study visit, conducted
3–12 months post-infection (April 2008 and January 2009) (Fig. 5).
Fig. 4. HI protection curve by age group, based on predictions from the logistic
model among ILI subjects at inclusion (ILI-A(H1N1) negative: subjects <30 years
old (n = 10), 30–50 years old (n = 26), >50 years old (n = 40); ILI-A(H1N1) positive:
subjects <30 years old (n = 11), 30–50 years old (n = 20), >50 years old (n = 8)).
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tig. 5. Evolution of GMT  according to ILI and A(H1N1) infection status at inclusion;
rror bars represent 95% CI.
I titers declined thereafter to GMT  41.5 [95CI: 34.8; 49.5] at the
ime of the 2010 study visit but remained signiﬁcantly higher
ompared to GMT  at inclusion (p = 0.0157). Whereas ILI-A(H1N1)
egative subjects maintained a stable GMT  throughout the study
eriod (p = 0.7502), GMT  among no-ILI subjects decreased steadily
p < 0.0001). GMT  was signiﬁcantly different between the three
LI groups at the 2009 (p = 0.0460) and 2010 (p = 0.0048) annual
tudy visits. GMT  among no-ILI subjects differed from ILI-A(H1N1)
ositive subjects at the 2009 study visit (p = 0.0230) and from ILI-
(H1N1) negative subjects at the 2010 study visit (p = 0.0118).
. Discussion
We  studied the relationship between HI titer and probability
f protection against seasonal 2007 inﬂuenza A(H1N1) infection in
hree age groups and explored how HI titer evolves over three years
2008 to 2010) according to ILI and infection status at inclusion.
ur analysis supports, among naturally infected subjects, previous
ndings with regard to the HI protection curve and identiﬁes dif-
erences according to age. We  found evidence to suggest elevated
I titers associated with seasonal 2007 A(H1N1) infection decrease
ost-infection, but persist into subsequent inﬂuenza seasons.
Previous studies demonstrating a positive association between
I titer and clinical protection have relied primarily on vaccine
tudy data [11,24]. Hobson et al. [11] cautioned that the estimated
I titer (18–36) associated with a 50% protection may  not be gen-
ralizable to naturally infected subjects, however this remains a
rominent outcome or endpoint in serological and vaccine efﬁ-
acy studies regardless of type of inﬂuenza exposure. We are the
rst, to our knowledge, to identify differences in the HI protection
urve according to age; age-related differences in susceptibility to
nﬂuenza infection are well established [3,5,26,27]. Furthermore,
ur results indicate that low antibody titer, particularly among
lder subjects, may  confer a signiﬁcant level of protection in the
ontext of natural infection. Our estimates of GMT  at inclusion
ssociated with 50% probability of protection, ranging from 8.9 to
0.8 according to age group, are comparable to a recent estimate
y Coudeville et al. (HI titer 17 (Credible Interval: 10; 29)) [24] as
ell as other published work [11,28,29]. However, one household
tudy found that 50% protection was associated with HI titer 255
CI: 1:62 to 1:917); the higher estimate attributed to the intensity
f exposures in the conﬁned setting of the home [30].
Our model of the relationship between HI titer and probability
f protection did not support the designation of a single thresh-
ld level [11] and is therefore depicted by a curve [24]. We found
hat probability of protection increased steadily with increasing HI
iter for HI titers ≤80; higher HI titers were associated with smaller33 (2015) 7015–7021 7019
increases in probability of protection. This phenomenon has been
observed previously for HI titers ≥150 [24,28].
After an initial peak following infection or vaccination, anti-
body titers decline before reaching a stabilized level maintained
over several years [31,32]. GMT  among ILI-A(H1N1) positive sub-
jects peaked at the time of the ﬁrst annual study visit. However,
due to the timing of this study visit (conducted 3–12 months post-
infection) GMT  at this time point likely captures the decline of HI
titers rather than the peak GMT  estimated to occur one month
post-infection [33–35]. Other studies have also documented rapid
GMT  decline after reaching peak levels post-infection [33,35,36],
however, our results also support recent ﬁndings showing persis-
tence of elevated HI titers beyond 12 months post-infection [8].
Several studies [37–39], including one based on a subset of this
cohort [15], suggested that previous seasonal A(H1N1) infection
may  have been protective against A(H1N1)pdm09 infection during
the 2009 H1N1 pandemic via a cross-reactive antibody response. It
is unlikely, however, that antibody persistence among ILI-A(H1N1)
infected subjects is due to boosting during study follow-up. There
is no known interaction between A(H3N2) (circulating during the
2008–2009 season) and A(H1N1) viruses. Regarding the pandemic
season, none of the subjects with laboratory conﬁrmed (n = 1) or
suspected infection (seroconversion, n = 6) were in the ILI-A(H1N1)
positive group.
GMT  decline among no-ILI subjects was  not surprising; anti-
body decline over time has been demonstrated [7,8,35] and may
explain recurrent seasonal inﬂuenza epidemics. In contrast, GMT
among ILI-A(H1N1) negative subjects remained stable throughout
the study. Twenty-seven of the 76 ILI-A(H1N1) negative subjects
were found to have laboratory-conﬁrmed inﬂuenza B at inclu-
sion, although, cross-reactive responses between inﬂuenza A and
B viruses have not been demonstrated [40]. Stable GMT  may sug-
gest effects from undetected respiratory viruses or asymptomatic
infections prior to study enrolment.
4.1. Strengths/limitations
This study is among few longitudinal studies investigating dura-
bility of the immune response [8,14]. Recent studies have primarily
focused on the 2009 A(H1N1) pandemic and/or duration of vaccine-
induced antibody response [33–35]; those investigating seasonal
inﬂuenza infection were conducted almost 30 years ago [2–4,41].
Finally, while infected subjects may  have also been identiﬁed by
seroconversion, this study relied on a virological deﬁnition of
infection, thus avoiding the sensitivity issues associated with a
serological deﬁnition [42].
Our results may  not be generalizable to children as this study is
based on adult subjects. However our estimate of HI titer associated
with 50% clinical protection against inﬂuenza among subjects <30
years old is comparable to recent ﬁndings from a randomized con-
trol trial investigating seasonal vaccination among children [29].
Another limitation of our study is the timing of the serological sam-
ples. Inclusion samples among ILI subjects were restricted to those
collected within 5 days of the inclusion visit, limiting the delay
between start of symptoms and blood collection. Nonetheless, we
cannot assure that blood collection was  performed before the start
of HI titer increase for all ILI subjects.
The HI protection curves are based on ILI subjects seeking medi-
cal care, however, it is possible that their baseline risk for infection
may  be different from the general population. Furthermore, our
study captures symptomatic infections among ILI subjects only;
infected subjects with mild symptoms [3] that did not meet our
deﬁnition of symptomatic illness and/or those with asymptomatic
infections [43] were not identiﬁed. We  are therefore unable to infer
how protection and antibody persistence changes over time among
asymptomatic subjects.
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Although determination of HI titer by the HI assay is the gold
tandard, its variability is well known and this is another limitation
or this study [42,44]. HI titer is the primary correlate of protection
gainst inﬂuenza infection, however the association between HI
iter and protection does not establish a direct mechanistic link.
ecent research has explored the potential protective roles of local
esponses in the respiratory tract [8,45,46]. Furthermore, the low
iters that we, and other studies [11,14,24], have found to correlate
ith protection may  indicate that antibody responses may  work
n conjunction with other immune responses [30,47,48] to protect
gainst infection. This may  partly explain the difference in HI pro-
ection curves between older and younger subjects. Temporal data
egarding cellular responses may  further understanding of clinical
rotection against inﬂuenza infection, however this was  outside
he scope of this seroepidemiological study.
. Conclusion
We  found a positive association between HI titer and probabil-
ty of protection among naturally infected subjects and identiﬁed
ifferences according to age. This analysis provides a rare look into
he persistence of the antibody response following natural seasonal
(H1N1) infection. Future studies should incorporate longitudi-
al data regarding other potential correlates of immunity, such as
ellular immune responses, to better understand the durability of
rotection following seasonal inﬂuenza infection.
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